4142:TPE
Adimmune Corp
17,25Â TWD
arrow_upward
+0,29%(+0,050) 1J
2 nov., 13:30:07 UTC+8 · TWD
search
Tous les symboles
| Symbole | Cours | Variation | % variat. |
|---|
insights_autoGénération des principaux insights pour 4142...
Ouverture
17,65Â TWD
Élevé
17,65Â TWD
Faible
17,25Â TWD
Cap. boursière
7,41Â Md
Vol. moyen
1,04Â M
Volume
731,10Â k
+Â haut sur 1Â an
22,50Â TWD
+Â bas sur 1Â an
16,40Â TWD
BPA
-0,34Â TWD
Actions en circulation
235,29Â M
Nombre d'employés
564
Ouverture
17,65Â TWD
Élevé
17,65Â TWD
Faible
17,25Â TWD
Cap. boursière
7,41Â Md
Vol. moyen
1,04Â M
Volume
731,10Â k
+Â haut sur 1Â an
22,50Â TWD
+Â bas sur 1Â an
16,40Â TWD
BPA
-0,34Â TWD
Actions en circulation
235,29Â M
Nombre d'employés
564
Articles
Sources : Web et partenaires du secteur de l'information
TradingView
·
il y a 18 minutes
Wall Street ouvre en hausse : Nasdaq +0,64 %, S&P 500 +0,46 %, Dow Jones +0,78 %
Invezz
·
il y a 5 minutes
Dow Jones progresse de 400 points, les actions IA rebondissent et le pétrole recule
Zonebourse Suisse
·
il y a 14 minutes
Wall Street : l'indice Dow Jones prend 0,8%
Boursier.com
·
il y a 54 minutes
Wall Street remonte après la purge, en attendant Apple et les 'midterms'
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
À propos de Adimmune Corp